Previous 10 | Next 10 |
VistaGen Therapeutics Inc. (NASDAQ:VTGN) traded today at a new 52-week high of $3.27. So far today approximately 1.8 million shares have been exchanged, as compared to an average 30-day volume of 3 million shares. VistaGen Therapeutics Inc. share prices have moved between a 52-week high ...
Shares of VistaGen Therapeutics (NASDAQ: VTGN) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and provided a corporate update after the market close on Tuesday. It wasn't VistaGen's finan...
These Current & Former Biotech Penny Stocks Have Seen A Strong Year So Far One of the great things about biotech penny stocks is the potential of these companies. There are very few places that offer this kind of early access to potentially life-saving treatments. If you take a ...
VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...
VistaGen Therapeutics, Inc. (VTGN) Q4 2021 Earnings Conference Call June 29, 2021 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief...
VistaGen Therapeutics (VTGN): FY GAAP EPS of -$0.49 misses by $0.27.Revenue of $1.09M beats by $0.21M.At March 31, 2021, the Company had cash and cash equivalents of approximately $103.1 million.PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in ...
PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) Management to host corporate update conference call and audio webcast today at 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif., June 29, 202...
VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference cal...
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and oth...
VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...